Marron, Thomas U.

An inflammatory cytokine signature predicts COVID-19 severity and survival

Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 2,605

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 1,294

Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 429

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 391

TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer

Park, M. D., Reyes-Torres, I., LeBerichel, J., Hamon, P., LaMarche, N. M., Hegde, S., Belabed, M., Troncoso, L., Grout, J. A., Magen, A., et al. (2023) · Nature Immunology

Immune cells in cancerImmune Cell Function and Interaction

Cited by 251

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Marron, T. U., Fiel, M. I., Hamon, P., Fiaschi, N., Kim, E., Ward, S. C., Zhao, Z., Kim, J., Kennedy, P., Gunasekaran, G., et al. (2022) · The Lancet Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 239

Considerations for treatment duration in responders to immune checkpoint inhibitors

Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., et al. (2021) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 137

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., et al. (2024) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 90

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma

Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 74

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman-Yassky, E., Ungar, B., et al. (2022) · Nature Medicine

Breast Cancer Treatment StudiesStatistical Methods in Clinical Trials

Cited by 30

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., et al. (2025) · Cancer Discovery

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 28